Fluorescence-based index from the Sofia Streptococcus pneumoniae fluorescent immunoassay: a prognostic tool for pneumococcal community-acquired pneumonia
Por:
Antuori, A, Gonzalez, P, Llop, A, Pillado, P, Quesada, MD, Giménez, M and Cardona, PJ
Publicada:
7 abr 2026
Ahead of Print:
1 mar 2026
Resumen:
Urinary antigen tests, such as the Sofia Streptococcus pneumoniae fluorescent immunoassay, provide rapid and specific detection of S. pneumoniae in community-acquired pneumonia. Although the assay is qualitative, it generates a semi-quantitative fluorescence-based index whose prognostic utility remains underexplored. This study evaluates the relationship between the Sofia S. pneumoniae index and clinical severity in pneumococcal community-acquired pneumonia (CAP). A cross-sectional study of 161 adults with pneumococcal CAP was conducted at a tertiary hospital. Patients with severe pneumonia (quick sequential organ failure assessment (qSOFA) >= 2: 10.5 vs 2.3 relative light unit (RLU); CURB-65 >= 3: 12.3 vs 2.3 RLU), ICU admission (12.1 vs 2.7 RLU), and 30-day mortality (14.0 vs 3.3 RLU) showed significantly higher median index values (P < 0.001). Area under the curves from receiver operating characteristic curve analysis were 0.75 for qSOFA >= 2, 0.79 for CURB-65 >= 3, 0.71 for ICU admission, and 0.79 for 30-day mortality. Thresholds identified for CURB-65 >= 3 prediction were 6.5 RLU (sensitivity: 79.2%; specificity: 75.9%), 4.2 RLU for qSOFA >= 2 (sensitivity: 80.4%; specificity: 64.0%), 12.1 RLU for ICU admission (sensitivity: 51.5%; specificity: 81.9%), and 12.7 RLU for 30-day mortality (sensitivity: 78.6%; specificity: 81.5%). A 10-point increase in the index was associated with higher odds of severe pneumonia (CURB-65 odds ratio [OR]: 1.95; qSOFA OR: 1.48), ICU admission (OR: 1.35), and 30-day mortality (OR: 1.42). The Sofia S. pneumoniae fluorescent index demonstrates significant prognostic value in pneumococcal CAP. It complements traditional severity scores, offering rapid, microbiologically precise insights for guiding management and identifying high-risk patients.
Filiaciones:
:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
Gonzalez, P:
Germans Trias & Pujol Univ Hosp, Lab Med Dept, North Metropolitan Clin Lab, Badalona, Spain
Llop, A:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
Pillado, P:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
:
Germans Trias & Pujol Univ Hosp, Microbiol Dept, North Metropolitan Clin Lab, Badalona, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Univ Autonoma Barcelona, Genet & Microbiol Dept, Cerdanyola Del Valles, Spain
Green Submitted, gold
|